MA54939A - Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 - Google Patents
Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2Info
- Publication number
- MA54939A MA54939A MA054939A MA54939A MA54939A MA 54939 A MA54939 A MA 54939A MA 054939 A MA054939 A MA 054939A MA 54939 A MA54939 A MA 54939A MA 54939 A MA54939 A MA 54939A
- Authority
- MA
- Morocco
- Prior art keywords
- hydroxypyridoxazepines
- nrf2 activators
- nrf2
- activators
- hydroxypyridoxazepines used
- Prior art date
Links
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 title 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806201P | 2019-02-15 | 2019-02-15 | |
| US201962931877P | 2019-11-07 | 2019-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54939A true MA54939A (fr) | 2021-12-22 |
Family
ID=69726636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054939A MA54939A (fr) | 2019-02-15 | 2020-02-11 | Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11945826B2 (enExample) |
| EP (1) | EP3924356A1 (enExample) |
| JP (1) | JP7602469B2 (enExample) |
| KR (1) | KR20210126676A (enExample) |
| CN (2) | CN118206566A (enExample) |
| AU (1) | AU2020222080C1 (enExample) |
| BR (1) | BR112021016042A2 (enExample) |
| CA (1) | CA3129955A1 (enExample) |
| CL (1) | CL2021002110A1 (enExample) |
| CO (1) | CO2021010930A2 (enExample) |
| IL (2) | IL285438B2 (enExample) |
| MA (1) | MA54939A (enExample) |
| MX (1) | MX2021009659A (enExample) |
| MY (1) | MY209603A (enExample) |
| PH (1) | PH12021551873A1 (enExample) |
| SG (1) | SG11202108257TA (enExample) |
| TW (2) | TWI880702B (enExample) |
| WO (1) | WO2020165776A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3833662T (pt) | 2018-08-20 | 2024-03-18 | Janssen Pharmaceutica Nv | Inibidores da interação proteína-proteína keap1-nrf2 |
| PH12021551873A1 (en) * | 2019-02-15 | 2022-05-23 | Glaxosmithkline Ip Dev Ltd | Hydroxypyridoxazepines as nrf2 activators |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| JP7524899B2 (ja) * | 2019-05-31 | 2024-07-30 | Ｕｂｅ株式会社 | ベンゾトリアゾール誘導体 |
| KR20240133727A (ko) | 2022-01-07 | 2024-09-04 | 추가이 세이야쿠 가부시키가이샤 | Nrf2 활성화 작용을 갖는 함질소 헤테로환 화합물 |
| TW202404984A (zh) * | 2022-04-28 | 2024-02-01 | 日商第一三共股份有限公司 | 苯并三唑化合物 |
| TW202345792A (zh) | 2022-04-28 | 2023-12-01 | 日商第一三共股份有限公司 | 苯并噻吩化合物 |
| WO2024047248A1 (en) * | 2022-09-02 | 2024-03-07 | Institut National de la Santé et de la Recherche Médicale | Use of nrf2 activators for the treatment of cerebral small vessel disease |
| AU2024314540A1 (en) | 2023-06-19 | 2025-11-27 | Chugai Seiyaku Kabushiki Kaisha | Crystal of nitrogen-containing heterocyclic compound having nrf2 activation effect |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2094651A1 (en) * | 2006-11-17 | 2009-09-02 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| AU2014369153B2 (en) * | 2013-12-18 | 2017-09-21 | Astex Therapeutics Limited | Nrf2 regulators |
| EP3307729B1 (en) | 2015-06-15 | 2020-09-02 | GlaxoSmithKline Intellectual Property Development Limited | Nrf2 regulators |
| RU2018101077A (ru) | 2015-06-15 | 2019-07-15 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Регуляторы nrf2 |
| PH12017502255B1 (en) * | 2015-06-15 | 2022-07-22 | Astex Therapeutics Ltd | Nrf2 regulators |
| US10201531B2 (en) * | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| US10364256B2 (en) * | 2015-10-06 | 2019-07-30 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as NRF2 regulators |
| KR20190088404A (ko) * | 2016-12-06 | 2019-07-26 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 3-(2,3-디히드로-1h-인덴-5-일)프로판산 유도체 및 nrf2 조절제로서의 그의 용도 |
| JP2020500918A (ja) * | 2016-12-12 | 2020-01-16 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｎｒｆ２レギュレーターとしてのｎ−アリールピラゾール |
| ES2901617T3 (es) * | 2016-12-14 | 2022-03-23 | Glaxosmithkline Ip Dev Ltd | Bisarilamidas como reguladores de NRF2 |
| WO2018109646A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 compounds |
| PH12021551873A1 (en) * | 2019-02-15 | 2022-05-23 | Glaxosmithkline Ip Dev Ltd | Hydroxypyridoxazepines as nrf2 activators |
-
2020
- 2020-02-11 PH PH1/2021/551873A patent/PH12021551873A1/en unknown
- 2020-02-11 US US17/429,088 patent/US11945826B2/en active Active
- 2020-02-11 JP JP2021547429A patent/JP7602469B2/ja active Active
- 2020-02-11 IL IL285438A patent/IL285438B2/en unknown
- 2020-02-11 KR KR1020217029193A patent/KR20210126676A/ko active Pending
- 2020-02-11 CN CN202410206971.5A patent/CN118206566A/zh active Pending
- 2020-02-11 CN CN202080014726.4A patent/CN113474349B/zh active Active
- 2020-02-11 EP EP20708180.3A patent/EP3924356A1/en active Pending
- 2020-02-11 IL IL313950A patent/IL313950A/en unknown
- 2020-02-11 WO PCT/IB2020/051100 patent/WO2020165776A1/en not_active Ceased
- 2020-02-11 CA CA3129955A patent/CA3129955A1/en active Pending
- 2020-02-11 SG SG11202108257TA patent/SG11202108257TA/en unknown
- 2020-02-11 MX MX2021009659A patent/MX2021009659A/es unknown
- 2020-02-11 MY MYPI2021004562A patent/MY209603A/en unknown
- 2020-02-11 BR BR112021016042-6A patent/BR112021016042A2/pt unknown
- 2020-02-11 AU AU2020222080A patent/AU2020222080C1/en active Active
- 2020-02-11 MA MA054939A patent/MA54939A/fr unknown
- 2020-02-13 TW TW113112455A patent/TWI880702B/zh active
- 2020-02-13 TW TW109104455A patent/TWI843806B/zh active
-
2021
- 2021-08-11 CL CL2021002110A patent/CL2021002110A1/es unknown
- 2021-08-19 CO CONC2021/0010930A patent/CO2021010930A2/es unknown
-
2024
- 2024-02-27 US US18/588,051 patent/US20240352034A1/en not_active Abandoned
-
2025
- 2025-02-14 US US19/054,254 patent/US20250313573A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL285438B1 (en) | 2024-08-01 |
| AU2020222080B2 (en) | 2022-05-19 |
| SG11202108257TA (en) | 2021-08-30 |
| TWI843806B (zh) | 2024-06-01 |
| CN113474349A (zh) | 2021-10-01 |
| MY209603A (en) | 2025-07-24 |
| JP7602469B2 (ja) | 2024-12-18 |
| CO2021010930A2 (es) | 2021-09-09 |
| CN113474349B (zh) | 2024-03-01 |
| IL285438A (en) | 2021-09-30 |
| IL285438B2 (en) | 2024-12-01 |
| JP2022520442A (ja) | 2022-03-30 |
| TW202440593A (zh) | 2024-10-16 |
| PH12021551873A1 (en) | 2022-05-23 |
| AU2020222080C1 (en) | 2022-09-29 |
| US20220204526A1 (en) | 2022-06-30 |
| CN118206566A (zh) | 2024-06-18 |
| CL2021002110A1 (es) | 2022-02-11 |
| WO2020165776A1 (en) | 2020-08-20 |
| US20250313573A1 (en) | 2025-10-09 |
| TW202045514A (zh) | 2020-12-16 |
| US11945826B2 (en) | 2024-04-02 |
| MX2021009659A (es) | 2021-09-08 |
| KR20210126676A (ko) | 2021-10-20 |
| TWI880702B (zh) | 2025-04-11 |
| US20240352034A1 (en) | 2024-10-24 |
| IL313950A (en) | 2024-08-01 |
| BR112021016042A2 (pt) | 2021-10-05 |
| AU2020222080A1 (en) | 2021-09-02 |
| CA3129955A1 (en) | 2020-08-20 |
| EP3924356A1 (en) | 2021-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54939A (fr) | Hydroxypyridoxazépines utilisées en tant qu'activateurs de nrf2 | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| EP4013496A4 (en) | THROMBOSOMES AS AN AGENT FOR REMOVING THE THROMBOCYTE AGGREGATION-INHIBITING EFFECT | |
| MA52486A (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| MA50589A (fr) | Compositions de pyrrolopyrrole en tant qu'activateurs de pyruvate kinase (pkr) | |
| MA46091A (fr) | Composés biaryles utiles en tant qu'immunomodulateurs | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| EP3883570A4 (en) | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | |
| EP3416948C0 (en) | Indacene bearing sulfonylureas as anti-inflammatory agents | |
| EP3953331A4 (en) | PYRAZOLESULFONAMIDES AS ANTITUMORS | |
| EP3442973A4 (en) | INNOVATIVE COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREFOR | |
| MA45153A (fr) | Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux | |
| MA46196A (fr) | Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| ITUA20161510A1 (it) | Composizione per colorare la fibra cheratinica | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
| EP3755311A4 (en) | INDANAMINE AS PD-L1 ANTAGONISTS | |
| MA50250A (fr) | Compositions de tétrahydroimidazo quinoléine utilisées en tant qu'inhibiteurs de cbp/p300 | |
| MA49841A (fr) | Carboxamides utilisées en tant qu'inhibiteurs de protéase spécifique de l'ubiquitine | |
| MA46878A (fr) | Composés de benzodiazolium en tant qu'inhibiteurs d'enac | |
| MA50013A (fr) | Analogues de benzoazépine utilisés en tant qu'agents inhibiteurs de la tyrosine kinase de bruton |